ClinicalTrials.gg
TerminatedNCT06665776Updated Jul 22, 2026

HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

An observational study in Solid Tumor Malignancy, sponsored by PharmaEssentia. Terminated at 6 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by PharmaEssentia · Observational

How we know

Why this study was terminated
Because the Phase I trial will not go forward, patient recruitment for the pre-screening study has been terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
485
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective observational research to explore the frequency of Human leukocyte antigen A allele 02:01 (HLA*02:01) and the expression status of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in cancer patients in Taiwanese population.

Read the detailed description

T cell receptor (TCR)-engineered T cells with high affinity to NY-ESO-1 epitope presented by HLA-A*02:01 are potential therapeutic strategy against solid tumor, which show exciting results in several clinical studies. However, the prevalence of patients expressing HLA-A*02:01 and NY-ESO-1 in Taiwanese population is still unknown. This research aims to explore the prevalence of cancer patients expressing HLA-A*02:01 and NY-ESO-1 in Taiwanese population. Eligible patients with triple-negative breast cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma excluding nasopharyngeal carcinoma, Lung squamous cell cancer, synovial sarcoma, esophageal squamous cell carcinoma, cervical cancer, or ovarian cancer will be enrolled. High resolution genotyping for HLA-A*02:01 and NY-ESO-1 expression status using IHC will be assessed in all enrolled patients. The frequency of HLA-A*02:01 allele and the prevalence of NY-ESO-1 positive expression will be analysed by pooled patient population and by specific tumor type.

02

Conditions studied

  • Solid Tumor Malignancy

Keywords

  • NY-ESO-1
  • HLA-A*02:01
  • Solid tumor
03

In context

Lead sponsor

PharmaEssentia is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with confirmed diagnosis of any of the following solid tumor:

  1. Head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma;
  2. Hepatocellular carcinoma;
  3. Lung squamous cell carcinoma;
  4. Synovial sarcoma;
  5. Triple-negative breast cancer;
  6. Esophageal squamous cell carcinoma;
  7. Cervical cancer;
  8. Ovarian cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and voluntarily sign an form (ICF).
  2. Adult aged ≥ 18 years at the time of informed consent (or other age required by local regulations).
  3. Confirmed diagnosis of any of the following solid tumor:

    1. Head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma;
    2. Hepatocellular carcinoma;
    3. Lung squamous cell carcinoma;
    4. Synovial sarcoma;
    5. Triple-negative breast cancer;
    6. Esophageal squamous cell carcinoma;
    7. Cervical cancer;
    8. Ovarian cancer
  4. Patient who received standard curative or palliative therapy including but not limited to any targeted therapy based on mutation status for their cancer, or patient with advanced solid tumors for which there is no accepted therapy, standard therapies are no longer effective, or the patient refuses additional standard therapy.
  5. (ECOG) Performance Status ≤1.
  6. Body weight ≥ 50 Kg.
  7. of ≥ 6 months.
  8. Patient who agrees to provide the tumor sample for NY-ESO-1 IHC staining, from either fresh or

Exclusion criteria

Exclusion Criteria:

  1. Known primary immunodeficiency (such as Severe Combined Immunodeficiency Disease or AIDS).
  2. Uncontrolled intercurrent illness which is not suitable for enrollment at the discretion of the investigator, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements.
  3. Currently confirmed diagnosis of at least 2 active cancers; patient who was cured of the other cancer [disease free period > 6 months] and currently has only one research targeted tumor can be enrolled.
  4. Untreated or symptomatic .
  5. History of organ transplantation or stem cell transplantation.
  6. Other conditions (e.g. previous use of any cell therapy) which are not suitable for enrollment at the discretion of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
485 participants (actual)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. The frequency of HLA-A*02:01 allele in patients with confirmed diagnosed solid tumor.

    To explore the frequency of HLA-A\*02:01 allele using genotyping with high resolution in all eligible patients with confirmed diagnosed solid tumor.

    Time frame: 1 day

  2. The prevalence of NY-ESO-1 positive expression in all tumor patients with HLA-A*02:01 allele.

    To explore the prevalence of NY-ESO-1 positive expression using immunohistochemistry (IHC) in all patients with HLA-A\*02:01 allele.

    Time frame: 1 day

07

Study locations

6 sites
  • Chang Gung Memorial Hospital, Chiayi Branch
    Chiayi City, Taiwan, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan 407219, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan 704, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan 11217, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan, Taiwan
  • Taipei Medical University Hospital
    Taipei, Taiwan, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in May 2026, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Oct 30, 2024
StartActual
Mar 14, 2023
Primary completionActual
May 27, 2026
CompletionActual
May 27, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06665776
Lead sponsor
PharmaEssentia
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Mar 14, 2023
Primary completion
May 27, 2026
Completion
May 27, 2026
Last update
Jul 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion